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Analysis of Ani s 7 and Ani 
s 1 allergens as biomarkers 
of sensitization and allergy severity 
in human anisakiasis
Leticia de las Vecillas1,6*, Pedro Muñoz‑Cacho3,6, Marcos López‑Hoyos2, 
Vittoria Monttecchiani1, Victoria Martínez‑Sernández4,5, Florencio M. Ubeira4,5 & 
Fernando Rodríguez‑Fernández1
The high frequency of infection by Anisakis simplex (A. simplex) has led to an increase in IgE 
sensitization, turning allergy to this parasite a relevant contemporary health problem. Improving the 
lack of conventional diagnosis test specificity is crucial to better understand these clinical scenarios. 
Specific IgE (sIgE) to A. simplex extract by ImmunoCAP (Anisakis‑sIgE) was determined in sera from 
403 blood donors (BD) from Cantabria (North of Spain) of which 51 subjects resulted sensitized. 
Among these latter, 47 were asymptomatic (sABD). The values of total IgE, prick‑test, Anisakis‑sIgE, 
and sIgE to Ani s 1 (anti‑rAni s 1) and Ani s 7 (anti‑rAni s 7) were compared between 46 sABD and 49 
A. simplex allergic patients. The IgE seroprevalence by ImmunoCAP among BD was 12.65%. Allergic 
patients and sABD showed significant differences in all serum biomarkers evaluated. The area under 
the curve was assessed for Anisakis‑sIgE (0.892), sIgE‑rAni s 1 (0.672) and sIgE‑rAni s 7 (0.668). After 
a severe reaction, significantly higher levels of Anisakis‑sIgE and sIgE anti‑rAni s 1 were detected. 
Determinations of sIgE by ImmunoCAP, Ani s 1 and Ani s 7 presented different sensitization patterns 
between allergic and asymptomatic individuals. The Ani s 1 allergen arises as a possible biomarker to 
detect patients at risk of suffering severe allergic reactions.
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sIgE anti-rAni s 7  Specific IgE-antibodies to recombinant Ani s 7 allergen
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rAni s 1  Recombinant Ani s 1 allergen
rAni s 7  Recombinant Ani s 1 allergen
ROC  Receiver operating curve
Anisakis simplex (A. simplex) is a nematode belonging to the Anisakidae family in whose life cycle participate 
fish, crustaceans and marine  mammals1. Humans can become an incidental host due to the ingestion of raw or 
uncooked fish harboring third-stage  larvae2. In the last decades the prevalence of infected fish by A. simplex has 
increased dramatically and in parallel, health problems associated with this parasite becoming a public health 
 concern3–6. In the center and the northern areas of Spain, there is a tendency of consuming fresh fish either raw 
or prepared using techniques requiring light cooking (e.g., hake and anchovies) which favors the contact with 
the live  larvae7–9.
It is generally accepted that an infection by Anisakis spp. larvae is required to produce symptoms in 
 humans10,11. After a first penetration of the gastrointestinal mucosa by live Anisakis larvae, the released antigens 
induce the production of IgE antibodies in response to the parasite  infection7,12–14. In subsequences exposures 
to the larvae, sensitized individuals can develop allergic IgE-mediated symptoms some minutes to hours after 
the intake of parasitized  fish15. Clinical manifestations can range from mild to moderate, (such as urticaria, 
angioedema, bronchospasm) or even  anaphylaxis13. The local mucosa damage produced by alive larvae may also 
induce gastrointestinal symptoms, such as dyspepsia, vomiting, abdominal  pain12,15,16. When these type of clini-
cal features are associated to IgE-mediated symptoms, patients suffer a gastro-allergic  anisakiasis7,17,18. Anisakis 
simplex sensitization has been also considered as a triggering and/or worsening factor of other diseases such as 
urticaria/angioedema and  dyspepsia13,19,20.
Due to the low specificity of traditional test such as skin prick test (SPT) and Anisakis-sIgE (ImmunoCAP)21, 
several authors proposed the use of component-resolved diagnosis (CRD) to investigate which allergens are 
responsible for a given allergic reaction. CRD is a relevant diagnostic tool that can provide relevant information 
on severity risks and can guide allergists on the management of allergic  patients17,22–25.
Fourteen A. simplex allergens have been described and classified in three groups according to its origin: 
excretory/secretory, somatic and cuticular  proteins7,17,26–28. The first group includes relevant major allergens as 
Ani s 1 and Ani s 7, which are frequently used to measure sIgE responses to A. simplex in different populations 
including non-symptomatic blood donors, fish processing workers and patients suffering gastroallergic anisa-
kiasis or chronic  urticaria9,17,29.
Recently, Viñas et al.30 reported that the presence of IgG and IgE antibodies to Ani s 1 and Ani s 3 allergens in 
serum can aid to differentiate between patients with and without urticaria in regions where Anisakis infections are 
frequent. Also, cross reactivity between A. simplex allergens and those from house dust mites (HDM) or shellfish 
among others has been proposed as the origin of positive sIgE to complete A. simplex extract (ImmunoCAP) in 
asymptomatic  population31,32.
However, the role of Ani s 1 and Ani s 7 allergens as biomarkers of severity in Anisakis-induced acute aller-
gic reactions were never evaluated. To address this issue, we compared the anti-Ani s 1 and anti-Ani s 7 sIgE 
responses in a population of sABD with that of a population of patients presenting acute allergic symptoms to 
this nematode.
Results
Population characteristics: demographics and consumption habits. Among 403 BD randomly 
selected, 381 referred to be asymptomatic when consuming fish and 47 of them presented with Anisakis-
sIgE > 0.35 KUA/L (sABD) (See Supplementary Fig.  S1 online). Gender and age were the only demographic 
variables with significant differences between allergic group and sABD (p < 0.001 and p = 0.01, respectively) 
(Table 1). Based on the anonymous questionnaire answers, the overall frequency of fish consumption did not 
show significant differences between groups (p 0.142). As expected, raw fish intake (57.4% in allergic vs. 31.1% 
in sABD; p = 0.011) and restaurant fish consumption (28.3% in allergic vs. 2.8% in sABD; p = 0.002) was more 
frequent in allergic patients (see Supplementary Table S1 online).
Thirty-one sABD accepted a follow up consultation 2 years after their recruitment. Most of them were still 
asymptomatic when eating fish except one of them who experienced an anaphylactic reaction after eating infected 
fish (undercooked see bass), 1 year after the inclusion date (see Supplementary Fig. S1 online).
Prevalence of Anisakis simplex sensitization and conventional diagnosis test results. Con-
sidering the population of 403 BD, the sIgE seroprevalence measured by ImmunoCAP (sIgE > 0.35 kUA/L) 
was 12.65% (n = 51). Median values of total IgE and Anisakis-sIgE in the allergic group were 366 IU/mL and 
37.80 kUA/L, respectively; and 35.15 IU/mL and 1.79 kUA/L in the sABD. These differences were statistically 
significant between both groups (p < 0.001) (Table  2a). Anisakis-sIgE distributed by classes revealed that the 
majority of the allergic patients (91.9%) presented with levels greater than 3.5 kUA/L (Class 3–6), the 79.6% 
above 8 kUA/L, the 73.5% above 10 kUA/L and the 63.2% above 17.5 kUA/L (see Supplementary Fig. S2a online). 
In the sABD group all IgE values were ≤ Class 4 and the 91.3% of which were below 17.5 kUA/L (Class 1–3) the 
83.4% below 8 kUA/L and 67.4% below 3.5 kUA/L (see Supplementary Fig. S2a online).
All allergic patients had a positive SPT (5.50 mm) and 13 out of 21 sABD tested (76.2%) were also positive 
(median 5.00 mm) with no significant differences between groups (p 0.074) (Table 2a).
Component‑resolved diagnosis test results. The sera from all allergic patients (n = 49) and 46 sABD 
were analyzed using the Trisakis-170 ELISA kit to detect specific anti-rAni s 1 and anti-rAni s 7 sIgE antibodies. 
Considering the group of allergic patients, 38/49 (77.5%) and 47/49 (95.9%) sera tested positive for rAni s 1 and 
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rAni s 7, respectively. Two sera negative for rAni s 7 tested also negative for rAni s 1 (double negatives). Three 
sera (6.1%) from the rAni s 7 positive allergic population (ODs = 0.12, 0.31 and 0.83) testing negative to rAni s 1 
were also negative by SPT. On the other hand, 24/46 (52.2%) and 41/46 (89.1%) sera from the sABD group tested 
positive for rAni s 1 and rAni s 7, respectively.
Interestingly, the statistical analysis of the allergic and sABD populations revealed significant differences 
(p < 0.001) between the percentages of sera testing positive for rAni s1 in the allergic (77.5%) versus the sABD 
population (52.2%), but not between the corresponding positive values for rAni s 7 in both populations (96% and 
89%, respectively; Table 2b). Significant statistical differences (p < 0.001) were also found when comparing the 
percentages of sera testing positive to both recombinant allergens (double positives) in the allergic population 
(77.6%) versus the sABD population (52.2%) (Table 2b).
Finally, it is noteworthy that, although the OD ELISA values may be not comparable when they fall out of the 
linear region of the ELISA curve, the mean serum sIgE OD values in the allergic group were also significantly 
Table 1.  Demographics and fish consumption habits. Allergic patients and sensitized asymptomatic blood 
donors to Anisakis simplex (sABD). Data extracted from an anonymous questionnaire. aInformation related to 
age and residency was collected in all allergic patients and in 44 and 42 of sABD, respectively. Occupation was 
registered in 31 allergic patients and in 35 ABD. bMean (standard deviation). *Significant differences.
Allergic patients (n = 49) sABD (n = 46) p value
Demographics
Females, % 60.4 25 < 0.001*
Agea,  yearb 54.96 (11.63) 48.32 (12.78) 0.010*
Coastal  residencya 83.7% 81% 0.734
Occupation related to fishery 12.9% 5.7% 0.311
Fish consumption habits
Frequency, n (%) No significant differences
Conservation, n (%) No significant differences
Restaurant consumption, n (%) 13 (28.3%) 1 (2.8%) 0.002*
Raw preparation, n (%) 8 (16.7%) 1 (2.3%) 0.020*
Species, n (%) No significant differences
Fish farm source, n (%) 7 (17.5%) 11 (44.0%) 0.021*
Tolerance of frozen fish 42 (91.3%) 44 (100%) 0.045*
Raw fish consumption 27 (57.4%) 14 (31.1%) 0.011*
Homemade fish-preserves No significant differences
Table 2.  Results of conventional and component-resolved diagnosis test. (a) Comparison of median values 
(IQR) between allergic patients and sABD. (b) Comparison of positives results in component-resolved 
diagnosis test. (c) Sensitivity and specificity of Trisakis 170 (rAni s 1, rAni s 7, or both) considering only 
allergic patients as true positives. Cut-off values: Anisakis-sIgE > 0.35 kUA/L; SPT ≥ 3 mm; rAni s 1 = 0.09 (OD); 
rAni s 7 = 0.05 (OD). aSPT were performed in 21 out of 46 sABD. OD, optical density. *Significant differences.
Allergic patients (n = 49) sABD (n = 46) p
(a)
Total IgE (IU/mL) 366 (105–692) 35.15 (14.67–116.25) < 0.001*
Anisakis-sIgE (kUA/L) 37.80 (9.01–88.75) 1.79 (0.79–5.50) < 0.001*
rAni s 1 (OD) 1.47 (0.22–1.69) 0.13 (0.01–1.30) < 0.005*
rAni s 7 (OD) 1.34 (0.77–1.67) 0.57 (0.18–1.40) < 0.005*
SPT (mm) 5.50 (4.50–9.00) 5.00a (2.87–6.12) 0.074
(b)
Positive rAni s 1, n (%) 38 (77.5%) 24 (52.2%) 0.009*
Positive rAni s 7, n (%) 47 (95.9%) 41 (89.1%) 0.206
Double positive 38 (77.6%) 24 (52.2%) 0.009*
Sensitivity Specificity PPV NPV
(c)
rAni s 1 61.3% 66.7% 77.5% 47.8%
rAni s 7 95.9% 10.9% 53.4% 71.4%
Double positive 47.8% 77.5% 61.3% 66.7%
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higher than in sABD (1.47 and 0.13 for sIgE-Ani s 1, 1.34 and 0.57 for sIgE anti-Ani s 7, respectively; p < 0.005; 
Table 2a).
Correlation analysis between sIgE measured by ImmunoCAP and component‑resolved diag‑
nosis and clinical symptoms. A still non-solved problem in Anisakis-induced allergy is to know which 
parasite allergens, among those inducing sensitization, are responsible of the allergic symptoms showed by many 
patients after being parasitized. Since, as showed above, the percentage of subjects having sIgE to Anisakis aller-
gens may be different in allergic and sensitized non-allergic populations, we investigated whether these differ-
ences can be related with clinical symptoms using a given cut-off.
As all analyzed sera were selected using the ImmnoCAP method, discrimination between groups was not 
possible at a cut-off value of ≥ 0.35 kU/L (class 1). However, when the cut-off was increased to ≥ 3.5 kU/L, a 
plateau in ImmunoCAP and CRD values (sIgE anti-rAni s 1 and anti-rAni s 7) was observed, suggesting that 
these methods could also be used to discriminate between symptomatic and asymptomatic populations (see 
Supplementary Fig. S2b, S2c and Table S2 online). For a sIgE to Anisakis cut-off of 3.5 kU/L, the obtained values 
for sensitivity and specificity were 84.9% and 58.8%, respectively. However, these values reached 100% when only 
classes 5 (50–99.9 kU/L) and 6 (≥ 100 kU/L) were considered. According to previously validated cut-off values 
for sIgE anti-rAni s 1 and anti-rAni s 7 (ELISA) to detect Anisakis sensitization, their ability to discriminate 
between allergic and non-allergic subjects was poor with 61.3% and 95.9% sensitivity for rAni s 1 and Ani s 7, 
respectively, but only 66.7% and 10.9% specificity, respectively (Table 2c).
To better evaluate the ability of Trisakis-170 recombinant allergens and ImmunoCAP to predict clinical 
symptoms in Anisakis-sensitized patients we performed a ROC analysis to calculate the better cut-off values for 
each allergen (Fig. 1; Table 3a). The area under the curve (AUC) for Anisakis-sIgE values by ImmunoCAP was 
0.892, while for rAni s 1 and Ani s 7 were 0.675 and 0.678, respectively. Differences between areas were statisti-
cally significant (p < 0.0001; Fig. 1).
When the Youden index was assessed for Anisakis-sIgE by ImmunoCAP the best reported cut-off point 
was ≥ 7.9 KUA/L showing a 79.59% sensitivity and 84.78% specificity. Positive likelihood ratio was 5.2 (IC 
95:2.6–10.5) and negative likelihood ratio 0.24 (IC 95: 0.1–0.4). However, for rAni s 1 and Ani s 7 extremely 
high cut-offs were required (OD > 1.464 and OD > 0.589 for Ani s 1 and Ani s 7, respectively) to achieve moderate 
values of sensitivity and specificity (51.02% and 86.9% for rAni s 1 and 81.6% and 52.17% for rAni s 7) (Table 3b; 
see Supplementary Table S2 online).
These results suggest that ImmunoCAP is better than CRD to predict the apparition of clinical symptoms 
of allergy after Anisakis infections. Nevertheless, the results obtained with CRD showing a better correlation of 
allergy symptoms with positivity to rAni s 1 versus rAni s 7 suggests that the former is more relevant in induc-
ing allergic symptoms during Anisakis infections than rAni s 7. In this sense, after comparing the levels of sIgE 
anti-whole Anisakis antigens (ImmunoCAP) and anti-rAni s 1, we find significant differences in mean values 
between patients who have suffered a severe reaction, compared with those who experiences mild to moderate 
reactions (Fig. 2a, b).
Table 3.  Receiver operating characteristics (ROC) curves and Youden Index cut-offs of Anisakis-sIgE 
(InmunoCAP), rAni s 1 (ELISA) and rAni s 7 (ELISA). (a) Comparison of receiver operating characteristics 
(ROC) curves of Anisakis-sIgE (InmunoCAP), rAni s 1 (ELISA) and rAni s 7 (ELISA). (b) Comparison of 
Youden index cut-offs of Anisakis-sIgE (InmunoCAP), rAni s 1 (ELISA) and rAni s 7 (ELISA). The sample was 
defined as positive group (n = 49; 51,58%), patients or blood donors with symptoms related to fish intake; and 
as negative group (n = 46; 48,42%), sensitized blood donor without symptoms after eating fish. Cut-off values: 
Anisakis-sIgE > 0.35 kUA/L; SPT ≥ 3 mm; rAni s 1 = 0.09 (OD); rAni s 7 = 0.05 (OD). aDeLong et al.51, bbinomial 
exact. cBCa bootstrap confidence interval (1,000 iterations; random number seed: 978). OD, optical density.
Anisakis-sIgE ~ rAni s 1 Anisakis-sIgE ~ rAni s 7 rAni s 1 ~ rAni s 7
(a) Comparison of ROC data
Difference between areas 0.217 0.214 0.00355
Standard  Errora 0.0440 0.0403 0.0503
95% confidence interval 0.131 to 0.304 0.135 to 0.293 − 0.0951 to 0.102
z statistic 4.946 5.304 0.0705
Significance level p < 0.0001 p < 0.0001 p = 0.9438
Anisakis-sIgE rAni s1 rAni s 7
(b) Youden Index
Youden index J 0.6437 0.3798 0.3381
95% Confidence  intervalc 0.4689 to 0.7471 0.1996 to 0.5035 0.1603 to 0.4725
Associated criterion > 7.9 > 1.464 > 0.589
95% Confidence  intervalc > 1.8 to> 26.6 > 1.34 to > 1.576 > 0.053 to> 1.165
Sensitivity 79.59 51.02 81.63
Specificity 84.78 86.96 52.17
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House dust mites (Dermatophagoides pteronyssinus) and shellfish (shrimp) sensitization in 
asymptomatic sensitized individuals. It is well known that A. simplex shares allergen epitopes with 
house dust mites (HDM) such as D. pteronyssinus (DPT), and  shellfish33. In this study, we observed that most 
of sABD (43 sera) tested also for sIgE antibodies to HDM and shrimp. However, although all these presented 
with variable amounts of sIgE anti-DPT (range: 2.86–978 kUA/L) only 6/43 seropositive sera to shrimp (range: 
0.00–3 kUA/L). In addition, a positive correlation was observed in the sABD between sIgE to DPT and shrimp 
with total IgE, Anisakis-sIgE and sIgE anti-rAni s 7 (Spearman’s Rho) (Table S3 online). Specifically, the highest 
R values (R ≥ 0.5) were obtained comparing total IgE versus sIgE to Anisakis by ImmunoCAP (R = 0.52), total 
IgE versus sIgE to DPT (R = 0.88), total IgE versus sIgE to shrimp (R = 0.62), sIgE to Anisakis by ImmunoCAP 
versus sIgE to rAni s 7 (R = 0.66), and sIgE to shrimp versus sIgE to DPT (R = 0.63). However, significant R values 
were also obtained for other combinations including Ani s 7 versus sIgE to shrimp or DTP (see Supplementary 
Table S3 online).
Discussion
It is well known that anisakiasis is a parasitic infection which may course or not with associated allergic symp-
toms. Currently, the demonstration that an allergic patient has specific circulating IgE antibodies induced during 
a previous infection by Anisakis can be done by several in vitro techniques. However, to predict which subjects 
having anti-Anisakis IgE antibodies are at a risk of suffering allergic symptoms after a second contact with the 
parasite, and to dilucidate which Anisakis allergens are clinically relevant are questions that remain to be solved. 
In the last years, precision medicine applied to A. simplex allergy has tried to discriminate between allergy, cross 
reactivity and asymptomatic sensitization to this parasite through molecular diagnosis, detecting sIgE to differ-
ent A. simplex major allergens such as Ani s 1 and Ani s  717,34,35. A possible way to investigate these problems is 
searching for differences in the Anisakis antigenic profiles recognized by sensitized—allergic—versus sensitized 
non-allergic subjects. As the number of commercially available Anisakis allergens is limited, and as a proof of 
concept, in this study we investigated with which frequency allergic and non-allergic Anisakis sensitized patients 
recognize the Ani s 1 and Ani s 7 allergens in Cantabria.
Considering the population of BD, our results show a seroprevalence of Anisakis-sIgE (tested by Immuno-
CAP) of 12.65% in Cantabria, which is consistent with previous studies carried out in other Spanish geographic 
 areas9. No seroprevalence values were obtained for rAni s 1 and Ani s 7 since only ImmunoCAP-positive sera 
were tested using the Trisakis-170 test. However, sABD tested also positive by Trisakis-170 (89.13%), we esti-
mated that a seroprevalence of 12–15% is expected in Cantabria. No significant differences between allergic 
Figure 1.  Receiver operating characteristics (ROC) curves of Anisakis-sIgE (InmunoCAP), rAni s 1 (ELISA) 
and rAni s 7 (ELISA). The sample was defined as positive group (n = 49; 51,58%), patients or blood donor 
with symptoms related to fish intake and as negative group (n = 46; 48,42%), sensitized blood donor without 
symptoms (sABD) after eating fish. Cut-off values: Anisakis-sIgE, 0.35  kUA/L; Ani s 1, 0.09; Ani s 7, 0.05. 
aDeLong et al.51, bbinomial exact. OD, optical density.
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patients and sABD were found in frequency of fish intake, which can be explained because Cantabria is a region 
with a high rate of fish consumption. On the other hand, gender and age showed differences between the group 
of allergic and sABD, which can be due to the fact that blood donors are usually young males meanwhile Th2-
driven allergic diseases are more prevalent in  females36 (Table 1).
When the cut-off of Anisakis-sIgE (tested by ImmunoCAP) was analyzed based on clinical features in allergic 
patients and in sABD, we observed that an increase from 0.35 to 7.9 kUA/L improved its clinical significance 
(likelihood ratio of 5.2–0.24). Thus, a positive test result will be 5.2 times more likely in patients with Anisakis 
allergy than in asymptomatic population, while a negative test is 4.2 times (i.e. 1/0.24) more likely in patients 
without Anisakis allergy.
Regarding the population of allergic patients, only two sera out of 49 (4.1%) tested negative by rAni s 7, while 
11/49 (22.4%) tested negative by rAni s 1. In our population, no serum tested positive to rAni s 1 and negative 
to rAni s 7. The proportions of sensitized patients against rAni s 7 and rAni s 1 in our allergic population were 
similar to those previously reported for patients with gastro-allergic anisakiasis or Anisakis-induced chronic 
 urticaria17 and confirm previous reports on the immunodominant IgE response to these allergens (mainly to 
Ani s 7) during the infections by A. simplex28,34,37. Like for the allergic population, the percentage of sera testing 
positive to Ani s 7 in the sABD group was also extremely high (41/46; 89.1%), this percentage dropped to 52.2% 
(24/46) for rAni s 1.
The high percentage of seropositivity to rAni s 1 in the allergic population (77.5%) and a lower value in the 
sABD population (52.2%), compared with the responses to rAni s 7 in both populations (95.9% and 89.1%, 
respectively), suggests that Ani s 1 is a clinically relevant allergen, or at least, more clinically relevant than Ani 
s 7. Although Ani s 7 is the most immunodominant reported Anisakis allergen, it also induces high levels of 
IgG4 antibodies during Anisakis acute infections (e.g. gastroallergic anisakiasis), which could have a protecting 
Figure 2.  Comparation of Anisakis-sIgE (InmunoCAP) and rAni s 1 (ELISA) results between allergic patients 
who suffered a mild to moderate reaction with those who experience a severe allergic reaction. (a) Values of 
Anisakis-sIgE (mean of 0.65 and 1.61, respectively; p = 0.002). (b) Values of sIgE to rAni s 1 (mean of 15.90 
and 72.60, respectively; p = 0.042). (c) Receiver operating characteristics (ROC) curves of Anisakis-sIgE 
(InmunoCAP) and rAni s 1 (ELISA) defined as positive group (n = 24; 48.98%), patients who presented a severe 
reaction after eating fish infected by AS and as negative group (n = 25; 51.02%), patients who presented mild to 
moderate reactions when eating fish infected by A. simplex. Cut-off values: Anisakis-sIgE > 0.35 kUA/L; Ani s 
1 = 0.09. aDeLong et al.51, bbinomial exact.
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role against developing some allergic symptoms (e.g., chronic urticarial) to this  allergen38. Moreover, the repeti-
tive structure variants composing this secreted  antigen37 suggests it may be involved in evasion of the immune 
response in the definitive natural host, for example, acting as a decoy antigen. In contrast, Ani s  139 is probably of 
higher clinical relevance because it is structurally related with the family of Kunitz-type serin protease inhibitors 
largely reported as clinically-relevant  allergens27,40.
Using a sample of 43 sera from the sABD population, we observed that all of them were also sensitized to 
DPT (IgE positive by ImmunoCAP) while only 6/43 (13.9%) tested positive for shrimp. As several Anisakis 
allergens (e.g. Ani s 3 and Der p 10—tropomyosin—or Ani s 2 and Der p 11—paramyosin) were reported to 
induce cross-reactive with mites, insects or  shrimp32,41, a doubt arises about whether the positive correlations 
observed between IgE to DTP, Anisakis and shrimp (see Supplemental Table S3 online) are due to cross-reactions 
or, alternatively, that such patients were sensitized to several allergens. Although based in the present data, none 
of the hypothesis can be totally discarded, some data suggests that concomitant sensitizations are more probable 
in our cohort of patients. While cross-reacting antigens (e.g., tropomyosin), which are present in Anisakis, DTP 
and shrimp, may boost IgE antibody responses to each other thus provoking false positive results in Immuno-
CAP (targeted with whole antigen mixtures), such cross-reactivity is improbable with Trisakis-170 analysis, 
mainly with Ani s 7. This hypothesis is supported by three facts: (1) the Ani s 7 allergen included in the kit is a 
polypeptide of 283 residues, which does not have relevant sequence identity with any know human  allergen37; no 
cross-reactions with mites were not previously reported for this allergen, and (2) there is experimental evidence 
that Cantabria is a region having one of the highest allergen concentrations of D. pteronyssinus (ref https ://alerg 
iaweb .files .wordp ress.com/2014/03/mapa-acaro lc3b3 gico-de-espac 3b1a-de-l-leti.pdf).
Comparing the results obtained between determinations of sIgE by ImmunoCAP and Trisakis 170 only 5 
sera were negative with the latter in the population of sABD. This raises the question of whether they are false 
sensitizations due to cross-reactivity that are frequently associated to the ImmunoCAP method or false negative 
results due to a small number of infected subjects that do not induce antibodies to Ani s 1/Ani s 7. Another pos-
sibility, that the test Trisakis 170 was less sensitive than ImmunoCAP seems less probable as this test detected 
patients with, as little as, 0.35 kUA/L by ImmnoCAP.
A preferential response to some other Anisakis allergens such as Ani s 4 (cystatin), Ani s 5 (SXP/RAL protein), 
Ani s 11 or Ani s 13 (haemoglobin)41–43, can explain that some sera test positive by ImmunoCAP and negative 
to Trisakis 170. Also, cross-reactions due to Ascaris infections was also reported as a possible cause of detecting 
sensitization to Anisakis in asymptomatic  patients30,44,45, which can be related with IgE responses to pan-allergens 
as paramyosin (Ani s 2)31,46.
In summary, in this study we reported for the first time 12.65% prevalence values of Anisakis sensitization in 
Cantabria. We showed a different intensity and frequency of response to Anisakis-sIgE measured by ImmunoCAP 
and Ani s 1 by ELISA, respectively, between A. simplex allergic patients and asymptomatic sensitized population. 
Also, higher frequency of recognition of the rAni s 1 allergen was found in patients who has experienced a severe 
reaction compare which those who had suffered a mild to moderate one (Fig. 2).
In consequence, anti-Anisakis sIgE ImmunoCAP values ≥ 7.9 kUA/L and high OD signals to the rAni s 1 
allergen could be potential biomarkers to recognize patients at risk of suffering severe allergic reaction after a 
re-infection by the parasite.
Materials and methods
All methods were carried out in accordance with relevant guidelines and regulations.
Study design, subjects and serum samples. A cross-sectional study with prospective data collec-
tion was performed at the Marques de Valdecilla University Hospital. The study was approved by the Clinical 
Research Ethics Committee of Cantabria (CEIC. Protocol number: 2016.074). All patients included in the study 
gave written informed consent for blood extraction, an anonymous survey about fish consumption habits and a 
subsequent consult if necessary.
The prevalence of IgE sensitization to A. simplex (Anisakis-sIgE > 0.35 KUA/L, ImmunoCAP) was investigated 
in a group of 403 BD randomly recruited at the Blood and Tissue Bank of Cantabria, Spain (control group) (see 
Supplementary Fig. S1 online). Among them, 51 subjects tested positive to Anisakis by ImmunoCAP, of which 47 
individuals reported no previous allergic/gastrointestinal symptoms after fish consumption, chronic urticaria or 
dyspepsia (sABD group) (see Supplementary Fig. S1 online). One serum was lost during storage, so the remain-
ing 46 sABD sera were used for further studies. Moreover, a follow up two years after the recruitment date was 
performed among this asymptomatic subgroup. The purpose was to verify if subjects belonging to the sABD 
group develop any clinical symptom after fish consumption during that time. In parallel, sera from 49 patients 
with allergy to A. simplex, were recruited for comparisons at the Allergy Department of Marques de Valdecilla 
University Hospital. On the inclusion day, a written survey (which included demographic data, fish consumption 
details and contact information) was completed by all subjects and a blood sample was collected. A Vacutainer 
SST II Advance (Becton Dickinson) tube was used to obtain and separate the serum sample. After a clot was 
formed, tubes were centrifuged at 2,000 g for 15 min at 25 °C. Serum was collected and stored at − 20 °C until use.
The group of allergic patients to A. simplex had experienced mild to severe allergic or gastrointestinal symp-
toms (urticaria, angioedema, dyspnea, nauseas, vomiting, abdominal pain, anaphylaxis) a few hours after eating 
suspicious A. simplex infected fish, presented with Anisakis-sIgE values greater than 0.35 KUA/L and sIgE to 
fish < 0.35 KUA/L11,47.
The sample size was determined previously assuming an A. simplex sensitization prevalence around 13%9,48 
for a population of 588,656 (https ://www.ine.es/jaxiT 3/Datos .htm?t=2893), considering a 5% precision and a 95% 
confidence level, to detect a meaningful difference (20–25%) in the main variables evaluated between groups.
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Skin testing and determination of Specific IgE to Anisakis simplex by ImmunoCAP. All allergic 
patients and 21 out of 47 of the enrolled sABD underwent SPT to A. simplex using commercial extracts (Labo-
ratorios LETI, Spain; 165 mcg/mL). SPTs were performed on the volar side of the forearm by using disposable 
1-mm-tip lancets and were also conducted with histamine (Roxall; 10 mg/ml) as positive and saline solution 
(0.9% NaCl) as negative controls. Readings were taken at 20 min after application. A mean wheal diameter of 
≥ 3 mm was considered positive. sIgE to whole A. simplex extract (Anisakis-sIgE) was determined by Immuno-
CAP system (Thermo Fisher Scientific Inc., Uppsala, Sweden) according to the manufacturer’s instructions. A 
positive result was considered Anisakis-sIgE > 0.35 kUA/l. The same method was used to determinate total IgE, 
and sIgE to fish.
Determination of specific IgE to rAni s 1 and rAni s 7 by ELISA. Fourty-six sABD and the 49 allergic 
patients (both groups with Anisakis-sIgE > 0.35 KUA/L) were analyzed by ELISA (Trisakis-170 ELISA. Parasitol-
ogy Laboratory at Santiago de Compostela University, Spain) to detect sIgE-Ani s 1 and sIgE-rAni s 7 allergens, 
as previously  described28,49,50. Cut off values (calculated absorbance) were considered OD = 0.09 for rAni s 1 and 
OD = 0.05 and rAni s  728,37.
Specific IgE to Dermatophagoides pteronyssinus and shrimp by InmunoCAP. sIgE to DPT and 
shrimp was determined by ImmunoCAP system (Thermo Fisher Scientific Inc., Uppsala, Sweden) in all allergic 
patients and in 43 sABD following the manufacture instructions.
Statistical analysis. To analyze possible associations between demographic characteristics (independent 
variables) and clinically relevant sensitization to A. simplex (dependent variable) a univariate and multivariate 
logistic regression analyses were used. Statistical analysis of diagnosis test results was carried out by logistic 
regression analysis and Receiver Operating Characteristics (ROC) curve. A p value of 0.05 or less was considered 
significant. The SPSS (version 20.0) software package was used for all data analyses. The correlation between 
serum levels were analyzed by MedCalc Statistical Software version 19.1 (MedCalc Software bvba, Ostend, Bel-
gium; https ://www.medca lc.org; 2019).
Ethics approval and consent to participate. A cross-sectional study with prospective data collec-
tion was performed at the Marques de Valdecilla University Hospital. The study was approved by the Clinical 
Research Ethics Committee of Cantabria (CEIC. Protocol Number: 2016.074). All patients included in the study 
gave written informed consent for blood extraction, an anonymous survey about fish consumption habits and a 
subsequent consult if necessary.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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